Predictors of Long-term Disability in Multiple Sclerosis: Real World Data from a Cohort of Egyptian Patients
International Clinical Neuroscience Journal,
Vol. 9 (2022),
10 January 2022
,
Page e22
Abstract
Background: Specification of prognostic factors in multiple sclerosis (MS) is crucial for clinicians to guide therapeutic protocols. This study aimed to identify demographic, clinical, and radiological factors associated with disability on a long-term basis in relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS).
Methods: This was a retrospective study conducted on patients with RRMS and SPMS with a disease duration of at least 10 years. Demographic, clinical, and radiological parameters were collected from the medical records.
Results: During the study period, 217 patients were recruited with a mean disease duration of 14.9 ± 4.6 (range: 10-35) years. Regression analysis revealed that age (B = 0.071, CI: 0.00-0.132, P = 0.025), male sex (B = –0.825, CI: –1.444 to –0.206, P = 0.009), duration between first 2 attacks (B = -0.007, CI: -0.015-0.000, P = 0.037), and involvement of pyramidal (B = 0.754, CI: 0.051-1.457, P = 0.036) or cerebellar domains (B = 1.355, CI: 0.542-2.168, P = 0.001) at disease onset were the only parameters that had an independent effect on EDSS.
Conclusion: Predictors of long-term disability in our cohort were closely similar, but not typically identical to predictors reported in the literature. Age, male sex, short duration between first 2 relapses pyramidal and cerebellar affection were the strongest predictors of disability in patients with RRMS and SPMS.
- EDSS; Early predictor; Long-term prognosis; Multiple sclerosis
How to Cite
References
Ghezzi A. European and American guidelines for multiple sclerosis treatment. Neurol Ther. 2018;7(2):189-94. doi: 10.1007/s40120-018-0112-1.
Arrambide G, Iacobaeus E, Amato MP, Derfuss T, Vukusic S, Hemmer B, et al. Aggressive multiple sclerosis (2): treatment. Mult Scler. 2020;26(9):1352458520924595. doi: 10.1177/1352458520924595.
Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis - success from bench to bedside. Nat Rev Neurol. 2019;15(1):53-8. doi: 10.1038/s41582-018-0082-z.
Zhang Y, Xu Y, Xu T, Yin H, Zhu Y, Peng B, et al. Prediction of long-term disability in Chinese patients with multiple sclerosis: a prospective cohort study. Mult Scler Relat Disord. 2020;46:102461. doi: 10.1016/j.msard.2020.102461.
Bermel RA, You X, Foulds P, Hyde R, Simon JH, Fisher E, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol. 2013;73(1):95-103. doi: 10.1002/ana.23758.
Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006;63(12):1686-91. doi: 10.1001/archneur.63.12.1686.
Mathey G, Pisché G, Soudant M, Pittion-Vouyovitch S, Guillemin F, Debouverie M, et al. Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course. J Neurol. 2021;268(10):3817-25. doi: 10.1007/s00415-021-10501-0.
Hamdy SM, Abdel-Naseer M, Shalaby NM, Elmazny AN, Nemr AA, Hassan A, et al. Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study. Neuropsychiatr Dis Treat. 2017;13:1895-903. doi: 10.2147/ndt.s140869.
Aktas O, Wattjes MP, Stangel M, Hartung HP. [Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017]. Nervenarzt. 2018;89(12):1344-54. doi: 10.1007/s00115- 018-0550-0.
Kurtzke. Expanded Disability Status Scale (EDSS). In: A Compendium of Tests, Scales and Questionnaires. Psychology Press; 2020. p. 603-605. doi:10.4324/9781003076391-169
Şen S. Neurostatus and EDSS Calculation with Cases. Noro Psikiyatr Ars. 2018;55(Suppl 1):S80-S3. doi: 10.29399/ npa.23412.
Sotiropoulos MG, Lokhande H, Healy BC, Polgar-Turcsanyi M, Glanz BI, Bakshi R, et al. Relapse recovery in multiple sclerosis: effect of treatment and contribution to long-term disability. Mult Scler J Exp Transl Clin. 2021;7(2):20552173211015503. doi: 10.1177/20552173211015503.
Bergamaschi R. Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision. Expert Rev Neurother. 2006;6(3):357-64. doi: 10.1586/14737175.6.3.357.
Hojjati SM, Hojjati SA, Baes M, Bijani A. Relation between EDSS and monosymptomatic or polysymptomatic onset in clinical manifestations of multiple sclerosis in Babol, northern Iran. Caspian J Intern Med. 2014;5(1):5-8.
Rolak LA, Olson B, ChyoU PH. Long-term follow-up of relapsing-remitting multiple sclerosis. J Neurol Neurosci. 2020;11(2):1-6. doi: 10.36648/2171-6625.11.1.314.
Bsteh G, Ehling R, Lutterotti A, Hegen H, Di Pauli F, Auer M, et al. Long term clinical prognostic factors in relapsing-remitting multiple sclerosis: insights from a 10-year observational study. PLoS One. 2016;11(7):e0158978. doi: 10.1371/journal.pone.0158978.
Claflin SB, Tan B, Taylor BV. The long-term effects of disease modifying therapies on disability in people living with multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord. 2019;36:101374. doi: 10.1016/j. msard.2019.08.016.
Fyfe I. Multiple sclerosis: real-world long-term benefits of disease-modifying MS therapy. Nat Rev Neurol. 2016;12(7):372. doi: 10.1038/nrneurol.2016.76.
Robertson D, Moreo N. Disease-modifying therapies in multiple sclerosis: overview and treatment considerations. Fed Pract. 2016;33(6):28-34.
Poliakov I, Metz LM. Effect of disease modifying therapies on long-term multiple sclerosis disability and mortality. Multiple Sclerosis Journal. 2016;22:76-77.
Chalmer TA, Baggesen LM, Nørgaard M, Koch-Henriksen N, Magyari M, Sorensen PS. Early versus later treatment start in multiple sclerosis: a register-based cohort study. Eur J Neurol. 2018;25(10):1262-e110. doi: 10.1111/ene.13692.
Minneboo A, Barkhof F, Polman CH, Uitdehaag BM, Knol DL, Castelijns JA. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol. 2004;61(2):217-21. doi: 10.1001/ archneur.61.2.217.
Tintore M, Rovira A, Arrambide G, Mitjana R, Río J, Auger C, et al. Brainstem lesions in clinically isolated syndromes. Neurology. 2010;75(21):1933-8. doi: 10.1212/ WNL.0b013e3181feb26f.
Brownlee WJ, Altmann DR, Alves Da Mota P, Swanton JK, Miszkiel KA, Wheeler-Kingshott CG, et al. Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome. Mult Scler. 2017;23(5):665-74. doi: 10.1177/1352458516663034.
Arrambide G, Rovira A, Sastre-Garriga J, Tur C, Castilló J, Río J, et al. Spinal cord lesions: a modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Mult Scler. 2018;24(3):301-12. doi: 10.1177/1352458517697830.
Li DK, Held U, Petkau J, Daumer M, Barkhof F, Fazekas F, et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology. 2006;66(9):1384-9. doi: 10.1212/01. wnl.0000210506.00078.5c.
Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59(9):1412-20. doi: 10.1212/01. wnl.0000036271.49066.06.
Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(10):1082-91. doi: 10.1136/jnnp-2012-304094.
- Abstract Viewed: 115 times
- PDF Downloaded: 137 times